Entactogenic drugs like MDMA and psychedelics like psilocybin may be beneficial for a range of psychiatric disorders. Though the pharmacology and subjective effects of entactogens and psychedelics differ, drugs that display qualities of both have received little attention to date.
A slew of contemporary research suggests MDMA’s efficacy as an adjunct in the treatment of PTSD, while little is known concerning the mechanisms at work. Recent investigation into the behavioral neurobiology of MDMA’s ability to facilitate the cessation of fear responses may offer a mechanistic explanation regarding its psychiatric utility.
MDMA-assisted therapy has been on the forefront of psychedelic research for years, but more recently patient safety concerns and research ethics have come into question.
We review the rise, fall, and rebirth of the infamous entactogen MDMA, the original ‘love drug’ and a promising tool for use in psychotherapy.
Psychedelics may hold the key to a novel PTSD treatment.
Dr. Rachel Yehuda shares details about an ongoing clinical trial involving MDMA-assisted psychotherapy to treat post-traumatic stress disorder in veterans.
MDMA supplements treatment of co-occurring trauma and eating disorders
Recent antidepressant exposure may reduce the treatment efficacy of MDMA.
The link between oxytocin and MDMA is less straightforward than once thought.
Psychedelic medicine continues to move forward, but minority communities are being left behind.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.
